{"entity":{"id":"nct04930432","kind":"trial","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of MCLA-129 in non-small-cell lung cancer and small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.","summary":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors is a phase 1/2 interventional study registered as NCT04930432 by Betta Pharmaceuticals Co., Ltd., with 400 participants planned, started 2021-09-24 and due to reach its primary completion in 2028-04-30. Interventions recorded: MCLA-129. Conditions listed: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04930432","url":"https://clinicaltrials.gov/study/NCT04930432"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["mcla-129"],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04930432","phase":"1/2","setting":"A Phase I/II Study of MCLA-129, a Human Anti-EGFR and Anti-c-Met Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors, Evaluating Safety, Pharmacokinetic Characteristics and Antitumor Activity","sponsor":"Betta Pharmaceuticals Co., Ltd.","participation":[{"nct":"NCT04930432","source":"https://clinicaltrials.gov/study/NCT04930432","fetchedAt":"2026-10-07T16:53:30.712Z","studySha256":"d5fa88e6bd627abeb0ffcc7780c55cd12f94226910d9a2e9ff5a789657bcccba","overallStatus":"RECRUITING","lastUpdatePosted":"2026-02-10","leadSponsor":"Betta Pharmaceuticals Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":400,"enrolmentType":"ESTIMATED","siteCount":87,"recruitingSiteCount":87,"countries":["China"]}],"started":"2021-09-24","startedType":"actual","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04930432/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"}]}}